Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.

Because caspase activation is an essential step in programmed cell death (apoptosis) and cytotoxic drug-induced apoptosis is mediated by caspase 2 and caspase 3, we hypothesized that caspase 2 and 3 levels predict clinical outcome in acute myelogenous leukemia (AML). Using quantitative Western blot analysis, we studied the levels of nonactivated (uncleaved) caspase 2 and 3 in peripheral blood low-density cells from 185 patients with newly diagnosed AML. We also measured the level of activated (cleaved) caspase 3 in 41 randomly selected samples from the 185 patients. Finally, we analyzed the effect of caspase 2 and 3 levels and other prognostic variables on patient survival using a multivariate Cox model. We found that median levels of nonactivated caspase 2 and 3 were higher in AML than in normal peripheral blood cells (P < .001 and P <.02, respectively). There was no association between caspase level and either the percentage of peripheral blasts or any specific type of leukemia cell cytogenetic abnormalities. When the effect of each uncleaved caspase was considered individually, a high level of uncleaved caspase 3 (P = .04), but not of caspase 2 (P = .16), was associated with decreased survival. Conversely, a high level of cleaved caspase 3 denoted improved survival and correlated with the inactivation of the DNA-repair enzyme poly(ADP-ribose) polymerase. Thus, cleaved caspase 3 could stimulate the apoptotic cascade further, and lack of its activation likely caused an accumulation of the uncleaved caspase. Although uncleaved caspase 2 level per se had no prognostic significance, the interactive effect of high levels of both uncleaved caspase 2 and 3 denoted very poor survival (P < .001) and had the largest effect of all prognostic variables (P < .001; estimated relative risk, 2.49; 95% confidence interval, 1.59 to 3. 90). Taken together, caspase 2 and caspase 3 protein levels obtained at diagnosis may constitute a reliable prognostic factor in AML.

[1]  Junying Yuan,et al.  Activation of Caspase-2 in Apoptosis* , 1997, The Journal of Biological Chemistry.

[2]  Sharad Kumar,et al.  Functional Activation of Nedd2/ICH-1 (Caspase-2) Is an Early Process in Apoptosis* , 1997, The Journal of Biological Chemistry.

[3]  R. Gascoyne,et al.  Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. , 1997, Cancer research.

[4]  S. Patterson,et al.  Selective Activation of Caspases During Apoptotic Induction in HL-60 Cells , 1997, The Journal of Biological Chemistry.

[5]  J. Yuan.  Genetic control of cellular suicide. , 1997, Reproductive toxicology.

[6]  P. Thall,et al.  Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Karp.  Acute leukemia: Mechanisms of cell survival as targets for therapy (review) , 1997 .

[8]  G. Stark,et al.  Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. , 1997, Science.

[9]  M. Groudine,et al.  Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. , 1997, Blood.

[10]  A. Suzuki,et al.  Involvement of CPP32/Yama-like protease in CPT-11-induced death signal transduction pathway. , 1996, Toxicology in vitro : an international journal published in association with BIBRA.

[11]  Junying Yuan,et al.  Human ICE/CED-3 Protease Nomenclature , 1996, Cell.

[12]  K. Bhalla,et al.  Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. , 1996, Cancer research.

[13]  E. Alnemri,et al.  Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. , 1996, Blood.

[14]  G. Lanfranchi,et al.  Chromosomal localization of the human genes, CPP32, Mch2, Mch3, and Ich-1, involved in cellular apoptosis. , 1996, Biochemical and biophysical research communications.

[15]  Z. Werb,et al.  Proteolysis and the biochemistry of life-or-death decisions , 1996, The Journal of experimental medicine.

[16]  M. Lavin,et al.  The ICE family of cysteine proteases as effectors of cell death. , 1996, Cell death and differentiation.

[17]  E. Estey,et al.  Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. , 1995, Blood.

[18]  Sharad Kumar,et al.  Role of multiple cellular proteases in the execution of programmed cell death , 1995, FEBS letters.

[19]  D. Nicholson,et al.  Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B , 1995, Nature.

[20]  Seamus J. Martin,et al.  Protease activation during apoptosis: Death by a thousand cuts? , 1995, Cell.

[21]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[22]  K O'Rourke,et al.  Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. , 1995, Cell.

[23]  P. Grambsch,et al.  Goodness-of-fit and diagnostics for proportional hazards regression models. , 1995, Cancer treatment and research.

[24]  E. Alnemri,et al.  CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. , 1994, The Journal of biological chemistry.

[25]  L. Wang,et al.  Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death , 1994, Cell.

[26]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[27]  J. Klein,et al.  Statistical Models Based On Counting Process , 1994 .

[28]  E. Estey,et al.  Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. , 1994, Blood.

[29]  S. Kumar,et al.  Identification of a set of genes with developmentally down-regulated expression in the mouse brain. , 1992, Biochemical and biophysical research communications.

[30]  D. Harrington,et al.  Counting Processes and Survival Analysis , 1991 .

[31]  S. Watt,et al.  An improved negative immunomagnetic selection strategy for the purification of primitive hemopoietic cells from normal bone marrow. , 1991, Experimental hematology.

[32]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[33]  J. Gershoni,et al.  Protein blotting: principles and applications. , 1983, Analytical biochemistry.

[34]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Wolfe,et al.  Nonparametric Statistical Methods. , 1974 .

[36]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[37]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.